{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:52:26Z","timestamp":1777452746444,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to determine the impact of inosine triphosphatase (ITPA) deficiency on ribavirin (RBV)-induced anaemia in HIV\u2013HCV-coinfected patients receiving a triple therapy including the haematotoxic direct-acting antiviral agent boceprevir (BOC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients of the ANRS HC27 BocepreVIH study were genotyped for two ITPA single nucleotide polymorphisms involved in ITPA deficiency. RBV trough concentration (C\n                      <jats:sub>trough<\/jats:sub>\n                      ) was determined at week (W)4 and W8. Impact of ITPA deficiency on anaemia, RBV C\n                      <jats:sub>trough<\/jats:sub>\n                      , response and haematotoxicity (grade 3\/4 anaemia, erythropoietin [EPO] use, RBV dose reduction or transfusion between day [D]0 and W8) was evaluated. Impact of RBV C\n                      <jats:sub>trough<\/jats:sub>\n                      on anaemia was also studied.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 63 genotyped patients, 33% had a predicted ITPA deficiency. ITPA deficiency was associated with a lower haemoglobin (Hb) decline both at W4 (-1.0 g\/dl versus -2.1 g\/dl; P=0.02) and W8 (-2.7 g\/dl versus -4.1 g\/dl; P=0.05). None of the patients with ITPA deficiency received EPO between D0\u2013W8 versus 26% of patients without ITPA deficiency ( P=0.01). RBV C\n                      <jats:sub>trough<\/jats:sub>\n                      was associated with Hb decrease both at W4 and W8 and an RBV C\n                      <jats:sub>trough<\/jats:sub>\n                      cutoff value of 2 \u03bcg\/ml was significantly associated with a W4 Hb decline &gt;2 g\/dl. Haematotoxicity was significantly associated with a lower W4 Hb level ( P=0.017), absence of ITPA deficiency ( P=0.018) and higher RBV C\n                      <jats:sub>trough<\/jats:sub>\n                      ( P=0.012). ITPA deficiency, W4 RBV C\n                      <jats:sub>trough<\/jats:sub>\n                      and gender were independent predictors of anaemia at W4. ITPA deficiency was not associated with virological response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      ITPA deficiency and RBV C\n                      <jats:sub>trough<\/jats:sub>\n                      are still predictive of RBV-induced anaemia in HIV\u2013HCV-coinfected patients treated with RBV combined with a first-generation direct antiviral agent.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3074","type":"journal-article","created":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T07:38:23Z","timestamp":1472715503000},"page":"461-469","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["ITPA Deficiency and Ribavirin Level are Still Predictive of Anaemia in HCV\u2013HIV-Coinfected Patients Receiving Ribavirin Combined with a First-Generation DAA (ANRS HC27 Study)"],"prefix":"10.1177","volume":"22","author":[{"name":"the ANRS HC27 BOCEPREVIH Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Kheloufi","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM Timone, Service de Pharmacocin\u00e9tique et Toxicologie, Marseille, France"},{"name":"CRO2 INSERM U911, Marseille, France"},{"name":"Centre R\u00e9gional de Pharmacovigilance Marseille Provence Corse, Service de pharmacologie clinique et pharmacovigilance, APHM Sainte-Marguerite, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Poizot-Martin","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM Sainte-Marguerite, Service d'Immuno-h\u00e9matologie clinique, Marseille, France"},{"name":"INSERM, UMR912 (SESSTIM), 13006, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolphe","family":"Garraffo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of Nice, H\u00f4pital Pasteur, Laboratoire de Pharmacologie, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Tavenard","sequence":"additional","affiliation":[{"name":"Rennes 1 University, Rennes, France"},{"name":"Rennes University Hospital, Department of Clinical Pharmacology, Rennes, France"},{"name":"INSERM 1414 CIC-P Clinical Investigation Centre, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Quaranta","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM Timone, Service de Pharmacocin\u00e9tique et Toxicologie, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Renault","sequence":"additional","affiliation":[{"name":"Rennes 1 University, Rennes, France"},{"name":"Rennes University Hospital, Department of Clinical Pharmacology, Rennes, France"},{"name":"INSERM 1414 CIC-P Clinical Investigation Centre, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Lavrut","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of Nice, H\u00f4pital Pasteur, Laboratoire de Pharmacologie, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9pato-Gastro-Ent\u00e9rologie, H\u00f4pital Saint-Joseph, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Halfon","sequence":"additional","affiliation":[{"name":"H\u00f4pital Europ\u00e9en, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Piroth","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, University Hospital, and UMR 1347, University of Burgundy, Dijon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bellissant","sequence":"additional","affiliation":[{"name":"Rennes 1 University, Rennes, France"},{"name":"Rennes University Hospital, Department of Clinical Pharmacology, Rennes, France"},{"name":"INSERM 1414 CIC-P Clinical Investigation Centre, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Lacarelle","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM Timone, Service de Pharmacocin\u00e9tique et Toxicologie, Marseille, France"},{"name":"CRO2 INSERM U911, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit \u2013 INSERM U941, Assistance Publique H\u00f4pitaux de Paris (AP-HP) - Saint-Louis Hospital, Paris, France"},{"name":"Paris VII - Denis Diderot University, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Solas","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM Timone, Service de Pharmacocin\u00e9tique et Toxicologie, Marseille, France"},{"name":"CRO2 INSERM U911, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"key":"bibr1-IMP3074","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"bibr2-IMP3074","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"bibr3-IMP3074","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn421"},{"key":"bibr4-IMP3074","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00778.x"},{"key":"bibr5-IMP3074","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2011036"},{"key":"bibr6-IMP3074","doi-asserted-by":"publisher","DOI":"10.1038\/nature08825"},{"key":"bibr7-IMP3074","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.016"},{"key":"bibr8-IMP3074","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.12.038"},{"key":"bibr9-IMP3074","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2010.00741.x"},{"key":"bibr10-IMP3074","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.22069"},{"key":"bibr11-IMP3074","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1796"},{"key":"bibr12-IMP3074","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31824bf778"},{"key":"bibr13-IMP3074","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.027"},{"key":"bibr14-IMP3074","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27022"},{"key":"bibr15-IMP3074","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir665"},{"key":"bibr16-IMP3074","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06473-11"},{"key":"bibr17-IMP3074","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir754"},{"key":"bibr18-IMP3074","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23302"},{"key":"bibr19-IMP3074","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir210"},{"key":"bibr20-IMP3074","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24058"},{"key":"bibr21-IMP3074","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12170"},{"key":"bibr22-IMP3074","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.05.017"},{"key":"bibr23-IMP3074","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12224"},{"key":"bibr24-IMP3074","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2015.1135553"},{"key":"bibr25-IMP3074","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"bibr26-IMP3074","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009482"},{"key":"bibr27-IMP3074","doi-asserted-by":"publisher","DOI":"10.1086\/376911"},{"key":"bibr28-IMP3074","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.05.010"},{"key":"bibr29-IMP3074","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-014-9574-0"},{"key":"bibr30-IMP3074","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12113"},{"key":"bibr31-IMP3074","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095881"},{"key":"bibr32-IMP3074","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0579-y"},{"key":"bibr33-IMP3074","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12376"},{"key":"bibr34-IMP3074","doi-asserted-by":"publisher","DOI":"10.1086\/656334"},{"key":"bibr35-IMP3074","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2929"},{"key":"bibr36-IMP3074","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04795-14"},{"key":"bibr37-IMP3074","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn013"},{"key":"bibr38-IMP3074","unstructured":"EASL. Recommendations on treatment of hepatitis C. 2014. (Accessed December 2014.) Available from http:\/\/www.easl.eu\/research\/our-contributions\/clinical-practice-guidelines\/detail\/recommendations-on-treatment-of-hepatitis-c-2015\/report\/4."}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3074","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:15Z","timestamp":1777380735000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.3851\/IMP3074"],"URL":"https:\/\/doi.org\/10.3851\/imp3074","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,1]]}}}